MedTrace Logo

Reversal of Remimazolam by a Single Dose of Flumazenil

NCT05382806 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 224

Last updated 2023-05-19

No results posted yet for this study

Summary

Remimazolam, a brand-new sedative which has benzodiazepine property. It is an ultra-short acting sedative and regarded as a proper drug for procedural sedation.

Conditions

  • Flumazenil Adverse Reaction
  • Ambulatory Surgery
  • Postoperative Nausea
  • Remimazolam

Interventions

DRUG

Flumazenil

During the procedure, continuous infusion of remimazolam dose of 2mg/kg/hr. when procedure ends, infusion remimazolam stops and 0.9% normal saline or 0.2mg of flumazenil according to allocated groups.

Sponsors & Collaborators

  • Konkuk University Medical Center

    lead OTHER

Principal Investigators

  • Seong-Hyop Kim, M.D. Ph.D · Konkuk University Medical Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-08-02
Primary Completion
2023-05-10
Completion
2023-05-13

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05382806 on ClinicalTrials.gov